Progressive nodular histiocytosis in a 9‐year‐old boy treated with cobimetinib. Issue 1 (21st December 2021)

• Record Type: Journal Article
• Authors: Buján, María Marta; Sánchez La Rosa, Cristian; Galluzzo Mutti, María Laura; Braier, Jorge; Diamond, Eli L.
• Is Part Of: Pediatric dermatology. Volume 39:Issue 1(2022)
• Page Start: 115
• Page End: 118
• Publication Date: 2021-12-21
• Subjects: cobimetinib -- non‐Langerhans histiocytosis -- progressive nodular histiocytosis; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.14887
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Progressive nodular histiocytosis is a rare variant of non‐Langerhans cell histiocytosis that affects the skin and mucous membranes and displays a progressive clinical course and poor response to treatment. We describe a case of severe progressive nodular histiocytosis harboring a KRAS p.G12S mutation in a 9‐year‐old boy, refractory to chemotherapy, who was successfully treated with the MEK inhibitor cobimetinib. This is the first report of the use of MEK inhibition for this histiocytosis subtype in a pediatric patient.